Literature DB >> 19798470

Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma.

Emmanouel Saloustros1, Ioannis Zaganas, Michail Mavridis, Lambros Vamvakas, Andreas Plaitakis, Vassilis Georgoulias, Dimitris Mavroudis.   

Abstract

Paraneoplastic cerebellar degeneration is a rare neurological disorder that frequently precedes the detection of malignancy. Here, we report the case of a 60 year-old woman with locally advanced squamous cell carcinoma of the tongue who developed a subacute cerebellar syndrome associated with the presence of anti-CV2/CRMP5 antibodies in the cerebrospinal fluid, after achieving complete remission of the primary tumor and the involved cervical lymph nodes by chemoradiation. The patient's symptoms on presentation were dizziness and gait unsteadiness. On examination she showed dysarthria, nystagmus and limb and gait ataxia. The diagnosis of paraneoplastic cerebellar syndrome was made on the basis of the clinical findings and immunological testing that revealed the presence of anti-CV2/CRMP5 antibodies in the patient's cerebrospinal fluid. This syndrome, which is very rare in association with head and neck cancer, commonly precedes the detection of malignancy by a year or more and has been documented in only a few cases after completion of anticancer treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19798470     DOI: 10.1007/s11060-009-0022-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

Review 1.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

2.  Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes.

Authors:  J Honnorat; T Byk; I Kusters; M Aguera; D Ricard; V Rogemond; T Quach; D Aunis; A Sobel; M G Mattei; P Kolattukudy; M F Belin; J C Antoine
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

3.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

4.  Management of paraneoplastic neurological syndromes: report of an EFNS Task Force.

Authors:  C A Vedeler; J C Antoine; B Giometto; F Graus; W Grisold; I K Hart; J Honnorat; P A E Sillevis Smitt; J J G M Verschuuren; R Voltz
Journal:  Eur J Neurol       Date:  2006-07       Impact factor: 6.089

5.  CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.

Authors:  Z Yu; T J Kryzer; G E Griesmann; K Kim; E E Benarroch; V A Lennon
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

6.  Bazex syndrome.

Authors:  K Buxtorf; E Hübscher; R Panizzon
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

7.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

Authors:  Setareh Shams'ili; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Herbert Hooijkaas; Bronno van der Holt; Charles Vecht; Peter Sillevis Smitt
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

9.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.

Authors:  J Honnorat; S Cartalat-Carel; D Ricard; J Ph Camdessanche; A F Carpentier; V Rogemond; F Chapuis; M Aguera; E Decullier; A M Duchemin; F Graus; J C Antoine
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10-17       Impact factor: 10.154

Review 10.  Paraneoplastic syndromes in patients with primary head and neck cancer.

Authors:  Alfio Ferlito; Mohamed N Elsheikh; Johannes J Manni; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-01-06       Impact factor: 3.236

View more
  4 in total

1.  Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma.

Authors:  A Aliprandi; A Terruzzi; A Rigamonti; E Bazzigaluppi; L Tremolizzo; C Ferrarese; A Salmaggi
Journal:  Neurol Sci       Date:  2015-02-17       Impact factor: 3.307

2.  Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Authors:  Florian Huemer; Thomas Melchardt; Wolfgang Tränkenschuh; Daniel Neureiter; Gerhard Moser; Teresa Magnes; Lukas Weiss; Alexander Schlattau; Clemens Hufnagl; Gerda Ricken; Romana Höftberger; Richard Greil; Alexander Egle
Journal:  BMC Cancer       Date:  2015-12-22       Impact factor: 4.430

Review 3.  Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review.

Authors:  Jinhua Yan; Zhongbo Chen; Yumei Liang; Huijia Yang; Lizhi Cao; Yuling Zhou; Yang Zhao; Ying Zhang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

4.  Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature.

Authors:  Juan José Juárez-Vignon Whaley; Aurelio Carrera-Muiños; Karol Gema Hernandez-Gutierrez; Jerónimo Rafael Rodriguez-Cid; Maria Elisa Otero-Cerdeira; Vanessa Garcia-Montes
Journal:  Case Rep Oncol       Date:  2021-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.